Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.
ABSTRACT A phase 2, randomized, multicenter, open-label study evaluated the safety and efficacy of albinterferon alfa-2b in interferon-alpha treatment-naïve patients with genotype 2/3, chronic hepatitis C virus infection.
Forty-three patients were randomly assigned in a 1:1 ratio to receive subcutaneous albinterferon alfa-2b 1500 microg every 4 weeks (q4wk) or every 2 weeks (q2wk) with oral ribavirin 800 mg/day for 24 weeks. Primary efficacy end point was sustained virologic response (undetectable hepatitis C virus RNA 24 weeks after completion of treatment). Insulin resistance was also assessed.
The safety of albinterferon alfa-2b was acceptable, with a similar adverse event profile in both treatment arms. Discontinuation as a result of adverse events occurred in 4.5% and 14.3% of patients in the q4wk and q2wk arms, respectively. No dose reductions caused by adverse events were reported in the q4wk arm versus 9.5% in the q2wk arm. Rapid viral response rates at week 4 were 68.2% and 76.2% for the q4wk and q2wk arms, respectively; the corresponding sustained virologic response rates were 77.3% and 61.9%. Insulin resistance at baseline was significantly associated with lower sustained virologic response rates independent of body mass index.
Albinterferon alfa-2b administered at 4-week intervals was safe and well-tolerated and demonstrated significant antiviral activity in patients with genotype 2/3, chronic hepatitis C virus. Insulin resistance appeared to have an independent effect on treatment response.
SourceAvailable from: docserver.ingentaconnect.com[Show abstract] [Hide abstract]
ABSTRACT: Albinterferon alfa-2b (albIFN) has been studied for the treatment of chronic hepatitis C virus infection in combination with ribavirin at different dose regimens ranging 900-1500 µg once every 2 (q2w) or 4 (q4w) weeks. Analyses on efficacy and safety exposure-response relationships in Genotype2/3 (G2/3) interferon-naïve patients were conducted to explore an improved risk-benefit of therapy. Data from 972 G2/3 patients were included in the exposure-response analysis. Major antiviral response endpoints of Sustained Virologic Response (SVR) and Rapid Virologic Response (RVR) exposure- response were modeled using logistic regression. The reported adverse event AE frequencies were tabulated vs quartiles of albIFN exposure. Body weight based exposure were estimated based on the population pharmacokinetic (PK) model and simulations were performed according to the weight based exposure and the exposure-response relationship. Within the G2/3 interferon-naive patients, albIFN Cavg but not Cmax or Cmin was associated with efficacy, along with certain baseline characteristics. For a given Cavg, dosing q2w was more active than q4w for RVR; Cavg was modestly associated with SVR, while no effect of dose interval was observed. Cavg was associated with a number of adverse events and laboratory abnormalities, especially at the higher exposure quartiles. The weight-based dose regimen (20 µg/kg) was predicted to decrease the subjects in the higher two quartiles of exposure by about half, compared with the fixed 1500 µg dose. This potential improvement was predicted to have a better overall safety profile with similar efficacy, but the overall reduction in AE’s would be small. As albIFN Cavg was significantly associated with both efficacy and safety outcomes, a weight-based regimen would be unlikely to significantly improve the risk benefit in comparison to the standard of care.01/2014; 12(1). DOI:10.2174/22113525113119990108
[Show abstract] [Hide abstract]
ABSTRACT: The effect of different formulations of interferon on therapeutic response in patients coinfected with HIV and HCV is unclear. In this study, the safety, tolerability, viral kinetics (VK) modeling and host responses among HIV/HCV coinfected patients treated with pegylated-IFN or albinterferon alfa-2b (AlbIFN) with weight-based ribavirin were compared. Three trials treated 57 HIV/HCV coinfected genotype-1 patients with PegIFN alfa-2b (1.5 µg/kg/week) (n = 30), PegIFN alfa-2a (180 µg/week) (n = 10), and AlbIFN (900 µg/q2week) (n = 17) in combination with weight-based ribavirin (RBV). HCV RNA, safety labs, and interferon stimulated gene expression (ISG) was evaluated. Adverse events were documented at all study visits. HCV viral kinetics using a full pharmacokinetic/pharmacodynamic model was also evaluated. Baseline patient characteristics were similar across the three studies. All three formulations exhibited comparable safety and tolerability profiles and efficacy. VK/PK/PD parameters for all three studies as measured by mean efficiency and rate of infected cell loss were similar between the three groups. Host responses (ISG expression and immune activation markers) were similar among the three groups. All three regimens induced significant ISG at week 4 (P < 0.05) and ISG expression strongly correlated with therapeutic response (r = 0.65; P < 0.01). In summary, a comprehensive analysis of responses to three different interferon formulations in HIV/HCV coinfected patients demonstrated similar effects. Notably, interferon-based therapy results in a blunted host response followed by modest antiviral effect in HIV/HCV coinfected patients. This suggests that future treatment options that do not rely on host immune responses such as direct antiviral agents would be particularly beneficial in these difficult to treat patients. J. Med. Virol. © 2013 Wiley Periodicals, Inc.Journal of Medical Virology 02/2014; 86(2). DOI:10.1002/jmv.23773 · 2.22 Impact Factor